Clinical Trial Update: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at Massachusetts General Hospital is evaluating venetoclax and obinutuzumab with or without acalabrutinib in relapsed/refractory chroni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)
• Venclexta (venetoclax)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING